Published in Drug Alcohol Depend on February 16, 2010
Gabapentin misuse, abuse and diversion: a systematic review. Addiction (2016) 1.47
Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev (2011) 1.15
Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep (2011) 1.07
5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice. Anesthesiology (2011) 0.94
Medical and psychological risks and consequences of long-term opioid therapy in women. Pain Med (2012) 0.88
Gabapentin in acute postoperative pain management. Biomed Res Int (2014) 0.87
Gabapentin Effect on Pain Associated with Heroin Withdrawal in Iranian Crack: a Randomized Double-blind Clinical Trial. Iran J Pharm Res (2012) 0.83
Preprotachykinin-A gene disruption attenuates nociceptive sensitivity after opioid administration and incision by peripheral and spinal mechanisms in mice. J Pain (2012) 0.82
Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin. Front Pharmacol (2015) 0.78
Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans. Addict Biol (2014) 0.77
Psychophysiology of pain and opioid use: implications for managing pain in patients with an opioid use disorder. Drug Alcohol Depend (2014) 0.76
Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon. Pain (2016) 0.75
Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain (2007) 6.98
Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA (2003) 4.25
Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology (2006) 3.81
Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag (2007) 2.59
Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal (2007) 2.43
Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain (2008) 2.38
Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesth Analg (2007) 2.29
Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain (2003) 2.18
Hyperalgesic responses in methadone maintenance patients. Pain (2001) 2.09
Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain (2008) 2.06
Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain (2001) 2.05
A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology (2005) 2.00
Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun (2006) 2.00
Antinociceptive and nociceptive actions of opioids. J Neurobiol (2004) 1.93
Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain (2006) 1.92
Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun (2008) 1.92
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther (2003) 1.85
Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers (2005) 1.83
Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci (2002) 1.78
Gabapentin prevents delayed and long-lasting hyperalgesia induced by fentanyl in rats. Anesthesiology (2008) 1.77
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend (2001) 1.77
Gabapentin: pharmacology and its use in pain management. Anaesthesia (2002) 1.69
Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proc Natl Acad Sci U S A (2005) 1.65
Gabapentin: a multimodal perioperative drug? Br J Anaesth (2007) 1.63
Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol (2007) 1.63
Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci (2002) 1.58
Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med (2006) 1.56
Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain (1998) 1.52
Mechanisms of the antinociceptive action of gabapentin. J Pharmacol Sci (2006) 1.43
Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience (2005) 1.38
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology (2003) 1.37
Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J Addict Dis (2007) 1.34
Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Med (2008) 1.31
Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend (2005) 1.31
Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep (2008) 1.29
Opioid tolerance and hyperalgesia. Med Clin North Am (2007) 1.28
Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology (2002) 1.26
A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res (2001) 1.24
Morphine and ibuprofen compared using the cold pressor test. Pain (1988) 1.22
The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat. Pain (2001) 1.22
Postoperative hyperalgesia: its clinical importance and relevance. Anesthesiology (2006) 1.20
Human pain responsivity in a tonic pain model: psychological determinants. Pain (1989) 1.17
Modulation of remifentanil-induced postinfusion hyperalgesia by propofol. Anesth Analg (2007) 1.17
Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manage (2000) 1.17
Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain (2006) 1.15
Effects of gabapentin on morphine consumption and pain in severely burned patients. Burns (2006) 1.13
Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett (2005) 1.13
Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage (1994) 1.13
Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience (1999) 1.09
Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med (2009) 1.08
Effects of oral morphine on cold pressor tolerance time and neuropsychological performance. Neuropsychopharmacology (1996) 1.06
The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol (2007) 1.06
Human experimental pain models in drug development: translational pain research. Curr Opin Investig Drugs (2007) 1.04
Treatment of pain in methadone-maintained patients. Mt Sinai J Med (2000) 1.03
Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol (2004) 1.03
Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology (2004) 1.02
A modified cold stimulation technique for the evaluation of analgesic activity in human volunteers. Pain (1985) 1.01
Antiepileptics and the treatment of neuropathic pain: evidence from animal models. Curr Pharm Des (2005) 1.00
Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res (1998) 1.00
Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. Can J Psychiatry (2008) 0.97
Hyperalgesia during acute opioid abstinence: evidence for a nociceptive facilitating function of the rostral ventromedial medulla. J Neurosci (1991) 0.96
A review of central neuropathic pain states. Curr Opin Anaesthesiol (2008) 0.96
Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain (2001) 0.96
Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep (2006) 0.95
Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann N Y Acad Sci (2006) 0.95
Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. Anesthesiology (2007) 0.95
System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol Rev (1996) 0.95
Efficacy of maintenance treatment with methadone for opioid dependence: a meta-analytical study. Nord J Psychiatry (2007) 0.94
Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain (2003) 0.93
Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. Neurosci Lett (1999) 0.93
The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg (1998) 0.93
The effects of remifentanil and gabapentin on hyperalgesia in a new extended inflammatory skin pain model in healthy volunteers. Anesth Analg (2004) 0.92
Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain (2005) 0.91
Pupillary and cardiovascular responses to the cold-pressor test. J Auton Nerv Syst (1995) 0.91
Spinal inhibitory neurotransmission in neuropathic pain. Curr Pain Headache Rep (2009) 0.90
Pain perception in drug-free and in methadone-maintained human ex-addicts. Proc Soc Exp Biol Med (1979) 0.90
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol (1998) 0.90
Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain (2006) 0.89
Update on pharmacotherapy guidelines for the treatment of neuropathic pain. Curr Pain Headache Rep (2006) 0.87
Mechanisms of pain in nonmalignant disease. Curr Opin Support Palliat Care (2008) 0.86
Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. Pharmacol Biochem Behav (2009) 0.86
Gabapentin reverses mechanical allodynia induced by sciatic nerve ischemia and formalin-induced nociception in mice. Exp Neurol (2003) 0.86
Effects of amitriptyline and gabapentin on bilateral hyperalgesia observed in an animal model of unilateral axotomy. Pain (2005) 0.86
Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs (2007) 0.85
Opioids: from analgesia to anti-hyperalgesia? Pain (2005) 0.84
Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients. Addict Biol (2008) 0.84
The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements. Anesth Analg (2001) 0.83
Effect of chronic oral gabapentin on capsaicin-induced pain and hyperalgesia: a double-blind, placebo-controlled, crossover study. Clin J Pain (2008) 0.83
Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain (2002) 0.82
Multiple dose gabapentin attenuates cutaneous pain and central sensitisation but not muscle pain in healthy volunteers. Pain (2006) 0.81
Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain (2006) 0.81
A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage (2007) 0.79
Pain management in the addicted patient: practical considerations. Nurs Outlook (2000) 0.79
Dextromethorphan attenuation of postoperative pain and primary and secondary thermal hyperalgesia. Can J Anaesth (2001) 0.79
Insights into the development of opioid tolerance. Pain (1995) 0.78
Adjuvant analgesics. Med Clin North Am (2007) 0.78
Ketamine blocks enhancement of spinal long-term potentiation in chronic opioid treated rats. Acta Anaesthesiol Scand (2008) 0.78
From pain research to pain treatment: the role of human experimental pain models. Best Pract Res Clin Anaesthesiol (2002) 0.77
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med (2003) 6.94
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (2011) 6.35
Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci (2004) 4.14
Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). Addiction (2008) 3.98
The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs (2003) 3.91
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry (2011) 3.15
Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry (2004) 3.02
DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry (2013) 2.89
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict (2004) 2.85
A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry (2002) 2.64
Smoking cessation in methadone maintenance. Addiction (2002) 2.62
Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology (2007) 2.42
A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction (2006) 2.30
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction (2013) 2.23
Medications development: successes and challenges. Pharmacol Ther (2005) 1.80
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr (2014) 1.79
Treatment for amphetamine withdrawal. Cochrane Database Syst Rev (2009) 1.75
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend (2008) 1.73
A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp Clin Trials (2010) 1.72
Will the methamphetamine problem go away? J Addict Dis (2002) 1.67
Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis (2002) 1.63
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction (2013) 1.63
Naltrexone and dysphoria: fact or myth? Am J Addict (2002) 1.56
Methamphetamine abstinence syndrome: preliminary findings. Am J Addict (2004) 1.49
Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend (2006) 1.47
A comparison of patterns of methamphetamine and cocaine use. J Addict Dis (2002) 1.45
Opiate recidivism in a drug-treatment program: comparison of hair and urine data. J Anal Toxicol (2003) 1.43
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend (2010) 1.41
Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry (2005) 1.40
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction (2013) 1.39
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend (2012) 1.37
Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry (2003) 1.36
Social networks, caregiver strain, and utilization of mental health services among elementary school students at high risk for ADHD. J Am Acad Child Adolesc Psychiatry (2003) 1.33
Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse (2011) 1.29
Agreement between CASA parent reports and provider records of children's ADHD services. J Behav Health Serv Res (2003) 1.25
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs (2013) 1.22
Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs? J Subst Abuse Treat (2010) 1.21
The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat (2004) 1.19
Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction (2002) 1.18
Child temperament, ADHD, and caregiver strain: exploring relationships in an epidemiological sample. J Am Acad Child Adolesc Psychiatry (2003) 1.17
Are health care providers still smoking? Data from the 2003 and 2006/2007 Tobacco Use Supplement-Current Population Surveys. Nicotine Tob Res (2010) 1.14
Long-term course of opioid addiction. Harv Rev Psychiatry (2015) 1.14
Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis (2002) 1.13
Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. J Addict Dis (2007) 1.13
A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med (2013) 1.11
Conducting clinical research with prescription opioid dependence: defining the population. Am J Addict (2010) 1.10
Management of methamphetamine abuse and dependence. Curr Psychiatry Rep (2006) 1.10
Traditional medicine in the treatment of drug addiction. Am J Drug Alcohol Abuse (2009) 1.09
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend (2008) 1.07
Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network. J Psychiatr Res (2011) 1.04
Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin Neurophysiol (2004) 1.03
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs (2014) 1.00
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend (2006) 0.99
Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network. J Subst Abuse Treat (2010) 0.99
Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network. Subst Abuse Rehabil (2010) 0.98
Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. Addict Behav (2003) 0.97
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend (2005) 0.97
Extent of documented adherence to recommended prenatal care content: provider site differences and effect on outcomes among low-income women. Matern Child Health J (2012) 0.96
Dancing with strangers: will U.S. substance abuse practice and research organizations build mutually productive relationships? Addict Behav (2002) 0.96
Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. Subst Use Misuse (2011) 0.95
Neonatal isolation alters stress hormone and mesolimbic dopamine release in juvenile rats. Pharmacol Biochem Behav (2002) 0.95
Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J Addict Dis (2002) 0.94
Predictors of outcome after short-term stabilization with buprenorphine. J Subst Abuse Treat (2012) 0.94
Comparing buprenorphine induction experience with heroin and prescription opioid users. J Subst Abuse Treat (2012) 0.93
Neonatal isolation enhances acquisition of cocaine self-administration and food responding in female rats. Behav Brain Res (2004) 0.93
Heightened cocaine and food self-administration in female rats with neonatal isolation experience. Neuropsychopharmacology (2006) 0.92
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology (2013) 0.92
Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clin Neurophysiol (2003) 0.92
Participant characteristics and buprenorphine dose. Am J Drug Alcohol Abuse (2011) 0.91
Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis (2008) 0.90
Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network. Subst Abuse Rehabil (2011) 0.90
Treatment for amphetamine psychosis. Cochrane Database Syst Rev (2009) 0.90
Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. Drug Alcohol Depend (2011) 0.90
Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. Qual Life Res (2011) 0.89
Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain (2006) 0.89
Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy. J Pain (2012) 0.89
A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend (2002) 0.89
Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. Contemp Clin Trials (2012) 0.88
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend (2008) 0.88
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction (2005) 0.88
Hypothalamic--pituitary-- adrenal axis dysregulation in women with irritable bowel syndrome in response to acute physical stress. West J Nurs Res (2009) 0.88
Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity (Silver Spring) (2007) 0.88
Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. Synapse (2005) 0.87
If a US drug abuse epidemic fails to include a major east coast city, can it be called an epidemic? J Addict Dis (2002) 0.86
Apathy predicts hedonic but not craving response to cocaine. Pharmacol Biochem Behav (2005) 0.86
Chronic neonatal isolation stress enhances cocaine-induced increases in ventral striatal dopamine levels in rat pups. Brain Res Dev Brain Res (2003) 0.86
The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. Addiction (2007) 0.86
Predictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program. J Community Health (2010) 0.86
Use of methamphetamine by young people: is there reason for concern? Addiction (2007) 0.86
Effect of oral ketorolac and gender on human cold pressor pain tolerance. Clin Exp Pharmacol Physiol (2003) 0.84
Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients. Addict Biol (2008) 0.84
Predictors of HAV/HBV vaccination completion among methadone maintenance clients. Res Nurs Health (2010) 0.83
Neurochemical and behavioral responses to cocaine in adult male rats with neonatal isolation experience. J Pharmacol Exp Ther (2005) 0.83
Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence. J Am Pharm Assoc (2003) (2005) 0.83
Neonatal isolation enhances maintenance but not reinstatement of cocaine self-administration in adult male rats. Psychopharmacology (Berl) (2004) 0.83
Injectable extended-release naltrexone for opioid dependence. Lancet (2011) 0.83
The effect of therapeutic touch on behavioral symptoms and cortisol in persons with dementia. Forsch Komplementmed (2009) 0.82